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Editorial
Challenges and proposed solutions for formative
research to inform systematic intervention
development in rare and unstudied conditions: The
case example of Xeroderma Pigmentosum
Background
The systematic development of interventions to change health behaviours that are
linked to morbidity and mortality is a key priority area for the discipline of health
psychology. There is, however, a gap in the provision of interventions to change
behaviour and improve health outcomes in rare diseases, although the behaviours
(e.g., photoprotection) and outcomes (e.g., avoidance of skin cancer) may not be
unique to the disease. A rare disease is one that affects fewer than five individuals per
10,000 in the general population (European Commission, 2008), but some may affect
far fewer people. A patient survey revealed that perceived unmet needs included the
absence or poor availability of social and psychological support (Rare Disease UK,
2013). A report on adherence in rare diseases further suggested that interventions to
improve self-management were needed, and should address perceptual (e.g., the need
for treatment, benefits, side effects), psychological (e.g., depression, coping), and
practical barriers (e.g., forgetting, routines; Cooper & Clatworthy, 2016). Despite this,
a PubMed search of randomized controlled trials (RCTs) of non-pharmacological
interventions in 6,632 recognized rare diseases revealed only one such trial (see
Kwakkenbos et al., 2013).
Together, these sources emphasize the urgent need for the development,
evaluation, and dissemination of behavioural and psychological interventions to
support people with rare diseases. Here, we summarize the key challenges faced
by intervention developers in rare diseases and, using xeroderma pigmentosum
(XP) as a case example, propose solutions to these challenges by distinguishing
between the novel aspects of rare diseases and those shared with more common
problems.
Case study: Xeroderma pigmentosum
Xeroderma pigmentosum is a very rare autosomal recessive disorder in which affected
individuals have a mutation in the genetic pathway responsible for the repair of DNA
damage caused by exposure to ultraviolet radiation (UVR) in daylight (Fassihi et al.,
2016). XP has an incidence in Western Europe of approximately 2.3 per million live
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births, although there are cross-country and cross-cultural differences in prevalence
(Lehmann, McGibbon, & Stefanini, 2011). Symptoms can include extreme sunburn
reactions following minimal sun exposure, abnormal pigmentation in sun-exposed
areas, progressive neurological degeneration (sometimes necessitating full-time care),
ophthalmological problems, and a 2,000-fold increase in the incidence of melanoma
skin cancers (10,000-fold increase in non-melanoma skin cancers). There are eight
complementation groups (XP-A to XP-G, and XP-V), which differ in their genetic and
concomitant symptom profiles (Fassihi et al., 2016). Diagnosis occurs in childhood for
those with an abnormal sunburn reaction and later when the sunburn reaction is
normal. The latter are often treated as non-XP melanoma patients until the frequency of
skin cancer prompts further investigation and diagnosis. There is no cure for XP, and
median life expectancy is 32 years (Bradford et al., 2011). The most important part of
clinical management involves rigorous photoprotection of the skin from UVR (Tamura,
DiGiovanna, Khan, & Kraemer, 2014), which includes reducing time spent outside in
daylight and achieving complete coverage using clothing and sunscreen when outside.
UVR exposure and photoprotection are integral in determining prognosis (morbidity
and mortality; Fassihi et al., 2016).
Although no research into adherence to photoprotection in XP exists, observations
of patients and their disease status/progression by the UK National XP clinical team
during regular clinic visits suggest that protection is often inadequate. Consequently, a 5-
year, mixed-methods study funded by the National Institute of Health Research (NIHR),
under their rare diseases call, is underway to identify the predictors of poor
photoprotection in patients with XP (phase I). This information will inform the
development of a toolbox of evidence-based, individualized behavioural and psycho-
logical interventions to improve photoprotection and health outcomes (phase II).
Initially, the intervention will be targeted at non-adherent adults with XP and will be
tailored according to the information provided by each patient in phase I (see Walburn
et al., 2017 for phase I protocol). If effective, there may be potential for adapting the
interventions for other XP groups (e.g., parents/carers); for use outside the United
Kingdom, where factors such as the provision of clinic-based support, climate, and
religion/culture are likely to differ; and for generalization to other rare diseases involving
photosensitivity or that require rigorous, and often restrictive, self-management. The
insights gained from such in-depth research into photoprotection behaviour may also be
relevant to general population sun protection, where intervention effectiveness in
improving protective behaviours and reducing UVR exposure has been limited (e.g.,
Rodrigues, Sniehotta, & Araujo-Soares, 2013; Williams, Grogan, Clark-Carter, & Buckley,
2013).
Challenges
The challenges associated with designing an intervention to improve photoprotection
behaviour in patients with XP, or any rare disease, can be described under three broad
categories:
1. Rarity – in the United Kingdom, there are ~100 patients who have been diagnosed
with XP. Further, there is considerable heterogeneity in this small group, including
varying ages and age of diagnosis, cognitive abilities (i.e., XP-related neurodegen-
eration, which limits the feasibility of research participation), and complementation
groups (each of which involves heterogeneity in symptoms and severity).
Photoprotection, and thus the need for, and type of, intervention, may also differ
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according to these features, although this is assumed rather than known. Any
attempt to quantitatively study this group is therefore going to be met with
difficulties in achieving adequate statistical power to detect meaningful predictors
of behaviour or between-group differences. Similarly, the conduct of a RCT to
determine intervention effectiveness will be limited by the small population.
2. Lack of availability of previous research – typically, previous research would guide
decision-making on methodological aspects of intervention design (e.g., definition
and measurement of behaviour; selection of theoretical framework; likely causal
mechanisms via which effects on behaviour/outcomes could be achieved). Scoping
searches (Google Scholar, EBSCO, Web of Science, Medline) using various search
terms in combination with XP returned few hits and no relevant empirical studies in
adults (the target population) using any method. Thus, little is known about the
experiences, impacts, or psychological characteristics of patients with XP (pre-
requisites for intervention design), and no interventions exist to improve behaviour
or outcomes in this population.
3. Patient burden – to conduct the necessary formative research to first understand
and predict photoprotection behaviour, researchers are reliant on a small group of
patients to participate in all methods, and with the hope that they remain in the
study, as there is no opportunity to ‘replace’ participants if attrition occurs. In
addition, study burden must be balanced with illness burden (e.g., frequent medical
appointments, lifestyle restrictions). Having participated in phase I, the same group
of participants will become the target population for the intervention, which means
that piloting is not possible, as patients involved in the pilot either cannot participate
in the trial or will do so ‘contaminated’. Similarly, the use of certain data collection
methods in an intensive phase I protocol (e.g., self-monitoring) may mean that
intervention participants are no longer representative of a na€ıve group, which could
affect implementation and dissemination outside of the trial. This is in stark contrast
to research in many other behaviours and conditions, where the various phases are
conducted in different samples drawn from the one larger target population.
Solutions for conducting formative research in rare diseases
‘Best practice’ intervention development typically involves following a systematic
approach (a review is beyond the scope of this editorial; Araujo-Soares, Hankonen,
Presseau, Rodrigues, & Sniehotta, unpublished data for a summary). Despite differences
between approaches, the steps related to formative research – that is, questions about
what needs to change (behaviour) and how such change might be achieved
(mechanisms/theory) – are remarkably similar. Figure 1 summarizes these steps,
focusing on the behaviour change wheel (Michie, Atkins, & West, 2014; which also
encompasses the Theoretical Domains Framework), intervention mapping (Bartholo-
mew Eldredge et al., 2016), and the UK Medical Research Council guidance on the
development and evaluation of complex interventions (Craig et al., 2008). As empha-
sized by each approach, the steps involved in intervention development are not
necessarily linear. In Figure 1, we also outline specific adaptations that were needed to
overcome the challenges in XP. Importantly, we are not advocating an entirely new
approach for rare diseases – all the elements of best practice remain (e.g., public and
patient involvement [PPI], stakeholder consultation) but the emphasis and reliance on
different sources of information to provide answers to inform intervention development
is necessarily different.
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What is already known?
In the absence or shortage of previous research on the specific rare disease, it may be
necessary to cast a wider and more creative search net to make meaningful use of the
literature that is available on similar behaviours and conditions (see Figure 1 for examples).
While similaritieswithotherpopulationswill inevitably exist, understanding thenuancesof
behaviour andpredictors in the context of the target rare disease is integral to the successful
matchingof intervention targets, techniques, andcontent, andany tailoring. InXP, there are
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qualitative (additional/different behaviours) andquantitative (intensity) differences inwhat
patients must do to achieve adequate photoprotection compared to other groups. For
example, wearing a face visor or buff are forms of protection that will be foreign to the
general population, and which likely carry additional barriers relating to comfort, visible
difference, and stigma (Anderson, Walburn, & Morgan, 2017), and will differ according to
contextual factors such as religion/culture. Regarding intensity, people with XP need to be
fully protected from UVR during daylight, regardless of factors such as the weather (e.g.,
sun, cloud coverage), time of day (i.e., not only during higher risk times: 11 am-3 pm), and
season (i.e., although cooler and with fewer daylight hours, protection is as essential in
winter as summer), as well as when indoors if daylight is able to penetrate windows (e.g.,
car, office). In contrast, recommendations for the general population are focused primarily
on sun protection in high risk contexts (i.e., summer/holiday periods, middle of the day).
Given the cumulative nature of UVR-inducedDNAdamage inXP, short exposures alsoneed
to be accompanied by rigorous photoprotection, whereas a period of unprotected time in
the sun is recommended for thegeneral population toprevent vitaminDdeficiency (Holick,
2007). Previous research can therefore provide a backdrop for decisions about the conduct
of original research, butmaynot otherwisedirectly contribute to interventiondevelopment
(denoted by grey text and arrows in Figure 1), where amore tailored approachmatched to
the specific context and behaviours will be required.
Original research
In rare diseases, original research is likely to be the major source of information
contributing to understanding the behaviour and its casual mechanisms (denoted by
bolded box in Figure 1). Methodologies that do not depend on sample size for power are
particularly well suited for rare diseases. Qualitative interviews are a mainstay in many
fields, and although not unique to rare diseases, represent a good starting point for
gathering an in-depth understanding of the patient perspective (Green & Thorogood,
2014), from which other methodologies can build. Questionnaire research may be
possible, if steps are taken to increase sample size (e.g., data collection in more than one
site/organization/country; done inXP), as suggested in the context of improving quality of
life for patients with the rare disease, scleroderma (Kwakkenbos et al., 2013).
Figure 1. Graphical summary of the steps involved in formative research for systematic
intervention development and suggested adaptations and change in emphasis for rare diseases.
Notes: Regular font (top of each box) = steps involved in existing approaches; bold/italic font
(bottom of each box) = adaptations for rare diseases; lighter text and bolded boxes/arrows indicate
additional changes in emphasis in rare diseases; BCTs = behaviour change techniques; BCW = be-
haviour changewheel; IM = interventionmapping; MRC = Medical Research Council guidance for
the development and evaluation of complex interventions; COM-B = capability opportunity
motivation-behaviour model; TDF = theoretical domains framework. Although understanding the
target behaviour and identifying the causal mechanisms/selecting a theory base may happen in
parallel (as both previous and original research contribute to answering these questions), a
comprehensive understanding of the former will also enable the latter; depending on what is
identified using previous and original research, the selection of a theory base may not involve using
one theory to the exclusion of others – instead, the theory base may include constructs and
mechanisms from various theories and in combinations that have not previously been tested (prior
to your study), if this approach provides the best fit to the data gathered.
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Finally, N-of-1 or single-case designs are recommended in rare diseases, as analysis is
concerned with within-participant temporal and contextual variation and power is
derived from repeated observations rather than the number of participants (McDonald
et al., 2017). The lack of generalizability (particularly when bespoke protocols are used)
that is sometimes a criticism of N-of-1 is also less relevant in rare diseases, where
personalized/tailored interventions are used and there is considerable overlap in the
formative and intervention samples. In XP, data from an N-of-1 study were used to gain a
comprehensive understanding of the target behaviour and to determine the intra-
individual predictors of variation in behaviour over time. The former included describing
the individual photoprotection behaviours and their relative degree of UVR protection;
variability in protection, within-participants over time and within an outdoor occasion;
and inferring the need for intervention based on the [in]adequacy of current levels of
protection. Only with this detailed understanding could we define a clinically meaningful
primary outcome, which allowed for the second task of identifying predictors of
photoprotection (Sainsbury et al., 2017).
In a mixed-methods project in a small population, balance needs to be struck between
adequate coverage/specificity and patient burden. This contrasts withmore common and
well-researched conditions, where different constructs can be assessed in separate
samples and previous research can aid the narrowing down of theoretical options. In XP,
decisions about thematch betweenmethodology and constructwere based onhowmuch
was known about the expression of the construct in patients and the ability of the team
(research, clinical, PPI) to formulate a directionally unambiguous and succinct question. If
the direction of the construct–behaviour relationship was known/assumed (e.g., habit),
constructs were included in a quantitative methodology; if insufficient knowledge meant
that the presence, nature, or direction of the relationship with photoprotection was
unknown (e.g., stigma), these were probed in the interviews (Anderson et al., 2017).
Within the quantitative methodologies, the anticipated stability (cross-sectional survey
with international data collection) or variation over time (N-of-1) of each construct
informed decisions.
Understanding the behaviour and causal mechanisms
The involvement of stakeholders (e.g., patients, clinical experts) is even more crucial in
rare diseases. Clinical recommendations regarding what patients should be doing (e.g.,
different forms of photoprotection in XP) may take a more prominent role in defining,
operationalizing, and measuring the target behaviour within the original research (e.g.,
using purpose-designed measures). Experts can also help to identify potential causal
mechanisms, by eliciting implicit assumptions about why certain patients adhere well,
while others continue to place themselves at risk. While experts will not think about the
problem or solution in ‘logic model’ terms, their wealth of patient-centred experience
places them in a good position to generate informed hypotheses that can be tested and
mapped to psychological theory. The XP clinical team held several causal beliefs – these
included the severity of the sunburn reaction (‘burners’ would protect better than ‘non-
burners’ due to the salience of consequences), age of diagnosis (adult diagnoses would be
associated with worse photoprotection, as the adjustment to protection and lifestyle
restrictions would be greater), and that risk perception was inaccurately based on how
sunny it was. Collected data were then triangulated with that for which questions were
generated by more standard means (i.e., previous research, common theoretical
mechanisms) to contribute a more detailed knowledge of the behaviour and its drivers.
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Reporting the findings
An additional consideration in rare diseases is balancing the need for transparent reporting
that places the results in sufficient context, while preserving the anonymity of patients in
small populations to guarantee them the same rights that members of a larger population
would have when participating in research. This is particularly so given the focus on
methodologies for which reporting tends to be at the individual rather than aggregate
level (i.e., N-of-1 and interview quotes). Levels of anonymity might include ensuring that
patients cannot be identified by their treating team, members of the public (e.g., friends/
family/work colleagues), and that they cannot identify themselves or other patients. Here,
we re-assigned participant ID numbers for publication; withheld demographic/clinical
details if these could lead to identification (e.g., age, age of diagnosis, complementation
group), as decided on a paper-by-paper basis and determined partly by the methodology
(e.g., N-of-1 uses within-participant analysis so static characteristics are less informative
for interpretation). Prior to submission, all papers will undergo a routine anonymity
screen by the research nurse, who is familiar with all study patients.
Conclusion
Although the challenges of working with rare diseases can be exciting, they also pose
several questions when considering recommendations for systematic intervention
development. We have outlined some solutions to these challenges that we believe will
help future researchers to conduct the necessary formative research to inform the
development of behavioural and psychological interventions to support self-management
and improve the health outcomes of individuals with rare diseases. Engaging in this
process will ensure that interventions in rare diseases have the best chance of being
effective; a concern that is perhaps even more important here, due to the impracticality
and patient burden associated with repeating this process if it does not work.
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